Bianca Weinstock-Guttman, MD

home / authors / bianca-weinstock-guttman-md

Articles

Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD
November 24th 2020
COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD
November 24th 2020
CLARITY Extension Trial: Disability Improvement With Cladribine

CLARITY Extension Trial: Disability Improvement With Cladribine

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD
November 24th 2020
Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD
November 24th 2020
Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD
November 24th 2020
Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD
November 24th 2020
Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD
November 24th 2020
OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD
November 24th 2020
OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD
November 24th 2020
Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD
November 24th 2020
Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD
November 24th 2020
Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD
November 24th 2020
OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD
November 24th 2020
OLKIOS: Looking at Ofatumumab’s Continued Efficacy

OLKIOS: Looking at Ofatumumab’s Continued Efficacy

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD
November 24th 2020
Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD
November 24th 2020

Latest Updated Articles

Kelsey E. Poisson, MD (Credit: Nationwide Children’s)
Published: November 27th 2024 | Updated: December 11th 2024
Race, Socioeconomic Status Play Major Role in Disparities Seen in Pediatric NMOSD Outcomes
Robert A. Hauser, MD, MBA (Credit: USF Health)
Published: October 17th 2024 | Updated: October 21st 2024
FDA Approves AbbVie’s 24-Hour Foscarbidopa/Foslevodopa Pump for Advanced Parkinson Disease Treatment
Jacob McCauley, PhD (Credit: Miami Miller School of Medicine)
Published: September 18th 2024 | Updated: September 20th 2024
Multi-Ethnic Study Identifies Ancestry-Specific Genetic Variants that Influence Risk of Multiple Sclerosis
Todd Sherer, PhD (Credit: The Michael J. Fox Foundation for Parkinson's Research)
Published: September 9th 2024 | Updated: September 11th 2024
FDA Supports Alpha-Synuclein Seed Amplification Assay Biomarker for Clinical Trials in Parkinson Disease
Lee Golden, MD (Credit: PTC Therapeutics)
Published: August 24th 2024 | Updated: August 26th 2024
Vatiquinone Pharmacokinetics Influenced by CYP3A4 Inhibitors and Inducers in Phase 1 Study
Renaud Du Pasquier, MD (Credit: University of Lausanne)
Published: August 22nd 2024 | Updated: August 23rd 2024
Novel Cell-Based Assay Enhances Detection of Autoantibodies in Neurological Disorders
© 2025 MJH Life Sciences

All rights reserved.